Rhinorrhea

Chronic Rhinosinusitis with Nasal Polyps Market to Witness Upsurge in Growth at a CAGR of 10.03% During the Study Period (2019-2032), Examines DelveInsight

Retrieved on: 
Thursday, December 7, 2023

LAS VEGAS, Dec. 7, 2023 /PRNewswire/ -- DelveInsight's Chronic Rhinosinusitis with Nasal Polyps Market Insights report includes a comprehensive understanding of current treatment practices, chronic rhinosinusitis with nasal polyps emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • Leading chronic rhinosinusitis with nasal polyps companies such as AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals, and others are developing novel chronic rhinosinusitis with nasal polyps drugs that can be available in the chronic rhinosinusitis with nasal polyps market in the coming years.
  • The promising chronic rhinosinusitis with nasal polyps therapies in the pipeline include FASENRA (benralizumab), TEZSPIRE (tezepelumab), Depemokimab/GSK3511294, CM310, NURTEC (rimegepant), and others.
  • Chronic rhinosinusitis is an inflammatory disease of the paranasal sinuses and nasal tube lining that lasts for more than 4 to 12 weeks.
  • To know more about chronic rhinosinusitis with nasal polyps treatment guidelines, visit @ Chronic Rhinosinusitis with Nasal Polyps Management

Chronic Rhinosinusitis with Nasal Polyps Market to Witness Upsurge in Growth at a CAGR of 10.03% During the Study Period (2019-2032), Examines DelveInsight

Retrieved on: 
Thursday, December 7, 2023

LAS VEGAS, Dec. 7, 2023 /PRNewswire/ -- DelveInsight's Chronic Rhinosinusitis with Nasal Polyps Market Insights report includes a comprehensive understanding of current treatment practices, chronic rhinosinusitis with nasal polyps emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • Leading chronic rhinosinusitis with nasal polyps companies such as AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals, and others are developing novel chronic rhinosinusitis with nasal polyps drugs that can be available in the chronic rhinosinusitis with nasal polyps market in the coming years.
  • The promising chronic rhinosinusitis with nasal polyps therapies in the pipeline include FASENRA (benralizumab), TEZSPIRE (tezepelumab), Depemokimab/GSK3511294, CM310, NURTEC (rimegepant), and others.
  • Chronic rhinosinusitis is an inflammatory disease of the paranasal sinuses and nasal tube lining that lasts for more than 4 to 12 weeks.
  • To know more about chronic rhinosinusitis with nasal polyps treatment guidelines, visit @ Chronic Rhinosinusitis with Nasal Polyps Management

Neurent Medical Announces New CPT Code® for Chronic Rhinitis Treatment Offering Significant Symptom Improvements

Retrieved on: 
Monday, November 13, 2023

GALWAY, Ireland, Nov. 13, 2023 /PRNewswire/ -- Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, today announced a significant milestone for the chronic rhinitis market. The Centers for Medicare and Medicaid Services (CMS) has recently assigned a Category I Current Procedural Terminology (CPT®) reimbursement code for a breakthrough minimally invasive procedure designed to address the symptoms of patients suffering from chronic rhinitis.

Key Points: 
  • GALWAY, Ireland, Nov. 13, 2023 /PRNewswire/ -- Neurent Medical , a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, today announced a significant milestone for the chronic rhinitis market.
  • The establishment of this CPT code is a significant milestone for physicians who treat chronic rhinitis patients.
  • The new code describes the procedure performed by otolaryngologists or ear, nose, and throat (ENT) physicians when disrupting overactive nerves that drive chronic rhinitis symptoms.
  • It is estimated that several million chronic rhinitis patients are seen by ENT doctors annually in the United States.

Aerin Medical Announces Advances for Chronic Rhinitis Treatment with New CPT® Code and Final CMS-Established Payment Rates

Retrieved on: 
Friday, November 3, 2023

The new code describes the procedure performed by ENT physicians when treating overactive nerves that drive chronic rhinitis symptoms with Aerin Medical’s RhinAer®.

Key Points: 
  • The new code describes the procedure performed by ENT physicians when treating overactive nerves that drive chronic rhinitis symptoms with Aerin Medical’s RhinAer®.
  • View the full release here: https://www.businesswire.com/news/home/20231031993246/en/
    CMS is set to implement a new CPT code that improves access to chronic rhinitis treatment with RhinAer® for patients often stuck in an unproductive cycle of care.
  • RhinAer is supported by a strong body of clinical evidence demonstrating significant, durable symptom improvement for chronic rhinitis patients.
  • Treatment with RhinAer is non-invasive and can be performed by ENT physicians in the office and outpatient surgical settings.

Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis

Retrieved on: 
Thursday, September 14, 2023

Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced further positive and statistically significant efficacy data from the randomized controlled NASAR clinical trial, which evaluated their Bentrio nasal spray in seasonal allergic rhinitis (SAR).

Key Points: 
  • Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced further positive and statistically significant efficacy data from the randomized controlled NASAR clinical trial, which evaluated their Bentrio nasal spray in seasonal allergic rhinitis (SAR).
  • The reduction in nasal symptoms conferred by Bentrio was 2.4 times larger than with saline nasal spray and clinically relevant.
  • Additional data, which have become subsequently available from the NASAR trial, confirm and reinforce the body of evidence demonstrating Bentrio’s efficacy in SAR management.
  • Further, the read-out from the NASAR trial suggest that Bentrio helps reduce the need for relief medication (cetirizine nasal spray).

Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results

Retrieved on: 
Tuesday, September 12, 2023

Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m.

Key Points: 
  • Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m.
  • ET
    Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs, today provided a business update and reported its first half 2023 financial results.
  • Net loss for the first half of 2023 was CHF 5.4 million compared with CHF 8.2 million for the first half of 2022.
  • ET to discuss its business update and first half 2023 results.

Hyloris has been granted EUR 1 million in non-dilutive funding from the Walloon Region

Retrieved on: 
Thursday, June 8, 2023

Stijn Van Rompay, Chief Executive Officer of Hyloris, commented: “We are grateful for the Walloon Region’s support of innovation happening at Hyloris, and minister of Innovation Willy Borsus in particular.

Key Points: 
  • Stijn Van Rompay, Chief Executive Officer of Hyloris, commented: “We are grateful for the Walloon Region’s support of innovation happening at Hyloris, and minister of Innovation Willy Borsus in particular.
  • This public funding will be used sparingly and prudently.”
    “Hyloris has been based in Liège for several years.
  • We have recently recruited heavily to expand our R&D team and will inaugurate an expanded lab facility in Liège in the coming weeks.
  • It occurs in around 7% of the total population, representing an estimated 19 million people in the US alone.

New Data show NEUROMARK® Chronic Rhinitis Treatment Offers Significant Symptom Improvements

Retrieved on: 
Tuesday, March 21, 2023

These data, published in Laryngoscope Investigative Otolaryngology , show that patients receiving the NEUROMARK therapy demonstrated significant improvement in rhinorrhea and nasal congestion symptoms at 3 months.

Key Points: 
  • These data, published in Laryngoscope Investigative Otolaryngology , show that patients receiving the NEUROMARK therapy demonstrated significant improvement in rhinorrhea and nasal congestion symptoms at 3 months.
  • NEUROMARK’s unique device and intelligent technology platform enable otolaryngologists to treat chronic rhinitis with precision and control, which in turn allows for an enhanced patient experience from treatment through recovery.
  • Total Nasal Symptom Score (rTNSS) and mini Rhinoconjunctivitis Quality of Life Questionnaire (mini RQLQ) score were also evaluated.
  • “We’re encouraged by the three-month CLARITY data demonstrating the safety, efficacy and relief from chronic rhinitis symptoms that can be achieved with NEUROMARK,” said Neurent Medical CEO Brian Shields.

Neurent Medical Announces Limited Market Release of NEUROMARK® System to Treat Chronic Rhinitis

Retrieved on: 
Friday, February 3, 2023

Neurent Medical , a company pioneering innovative non-surgical interventions to treat chronic inflammatory sino-nasal diseases, today announced its NEUROMARK® Rhinitis Neurolysis Therapy (RNT) is now commercially available in limited U.S. markets.

Key Points: 
  • Neurent Medical , a company pioneering innovative non-surgical interventions to treat chronic inflammatory sino-nasal diseases, today announced its NEUROMARK® Rhinitis Neurolysis Therapy (RNT) is now commercially available in limited U.S. markets.
  • Commercialization comes as the American Medical Association (AMA) issued a new Category I Current Procedural Terminology (CPT®) code for posterior nasal nerve ablation (PNN) procedures, which includes NEUROMARK, to treat chronic rhinitis.
  • NEUROMARK’s unique device and intelligent technology platform enable Otolaryngologists to treat chronic rhinitis patients with precision and control and enhance the patient experience from treatment through recovery.
  • The recent endorsement2 of PNN by the AAO-HNS, a specialty society representing almost 12,000 ENT surgeons, further validates Neurent Medical’s long-term future in the treatment of chronic rhinitis.

Altamira Therapeutics Provides Update on Clinical Trials with Bentrio

Retrieved on: 
Tuesday, January 24, 2023

The treatment effect of 1.55 points in favor of Bentrio was statistically significant in the ANCOVA model (LSmeans; p = 0.015; 95% confidence interval -2.78 to -0.32).

Key Points: 
  • The treatment effect of 1.55 points in favor of Bentrio was statistically significant in the ANCOVA model (LSmeans; p = 0.015; 95% confidence interval -2.78 to -0.32).
  • The interim analysis further showed good tolerability and safety both for Bentrio and the comparator.
  • Participants were randomized at a 1:1 ratio to either receive Bentrio or saline spray via self-administration three times per day, or as needed.
  • “We are very excited about the strong efficacy signals observed with Bentrio at the halfway point of the NASAR seasonal allergic rhinitis trial in Australia,” commented Thomas Meyer, Altamira Therapeutics’ founder, Chairman, and CEO.